Compare NAMS & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAMS | CRGY |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | 2022 |
| Metric | NAMS | CRGY |
|---|---|---|
| Price | $34.89 | $12.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $46.75 | $14.36 |
| AVG Volume (30 Days) | 794.4K | ★ 8.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.79% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $3,579,782,000.00 |
| Revenue This Year | $17.96 | $29.90 |
| Revenue Next Year | $540.65 | N/A |
| P/E Ratio | ★ N/A | $99.08 |
| Revenue Growth | N/A | ★ 22.14 |
| 52 Week Low | $14.92 | $7.68 |
| 52 Week High | $42.00 | $14.02 |
| Indicator | NAMS | CRGY |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 52.67 |
| Support Level | $34.05 | $8.29 |
| Resistance Level | $37.43 | $14.02 |
| Average True Range (ATR) | 1.69 | 0.57 |
| MACD | 0.59 | -0.15 |
| Stochastic Oscillator | 90.80 | 41.80 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.